Proxygen Appoints Chiara Conti as CSO to Accelerate Molecular Glue Platform Into Clinical Development
核心洞察
Proxygen (搜索) has appointed Chiara Conti, Ph.D., as Chief Scientific Officer to lead the company's transition from discovery to clinical-stage execution of its molecular glue degrader platform.
Dr. Conti brings extensive experience from Blueprint Medicines, where she identified four development candidates in seven years and established the company's targeted protein degradation (搜索) platform.
The appointment comes as Proxygen (搜索) expands beyond degradation into broader induced proximity therapeutics, aiming to address high-value targets across oncology (搜索) and other therapeutic areas.
Vienna-based biotechnology company Proxygen (搜索) announced the appointment of Chiara Conti, Ph.D., as Chief Scientific Officer, marking a strategic move to accelerate its molecular glue degrader platform into clinical development. The appointment positions the company to advance its proximity-based therapeutics from discovery into clinical-stage programs.
Leadership Transition to Clinical Focus
Dr. Conti joins Proxygen (搜索) from Blueprint Medicines, where she demonstrated exceptional productivity in drug development over seven years. During her tenure, she identified four development candidates, with two advanced to IND status with unprecedented speed while supporting two additional clinical programs in Phase I. She also established Blueprint's targeted protein degradation (搜索) (TPD) platform and early-stage portfolio.
"Over the past five years, we have built one of the most advanced discovery engines for molecular glue degraders (搜索), consistently delivering differentiated assets," said Bernd Boidol, Ph.D., Chief Executive Officer of Proxygen (搜索). "Chiara's appointment comes at a pivotal moment as we are now expanding into the broader induced proximity field, extending beyond degradation into a wider range of effectors."
Platform Expansion Strategy
Proxygen (搜索)'s strategic vision extends beyond traditional protein degradation approaches. The company is expanding its platform to encompass broader induced proximity mechanisms, representing what Boidol describes as moving "induced proximity from a discovery paradigm to a scalable, design-driven therapeutic modality."
"I have known Proxygen (搜索) since its establishment and followed its innovation over the years," said Dr. Conti. "Proxygen's platform stands out for the depth of its scientific foundation in proximity-driven protein degradation and its ability to systematically harness that knowledge to identify novel therapeutics. The opportunity to extend this platform beyond degradation into a broader induced-proximity engine is incredibly compelling."
Dual Development Approach
The company plans to maintain investment in its degradation platform while simultaneously expanding into new effector classes. This dual strategy reflects Proxygen (搜索)'s belief that induced proximity represents a versatile therapeutic approach capable of addressing high-value targets beyond current drug discovery limitations.
Proxygen (搜索) combines computational design, chemical biology, and functional genomics to systematically discover and develop proximity-based therapeutics. The platform targets applications across oncology (搜索) and other therapeutic areas, positioning the company to address previously undruggable targets.
Industry Validation
The appointment comes amid growing pharmaceutical industry interest in proximity-based therapeutics. Proxygen (搜索) has established multiple pharmaceutical partnerships, including with Merck & Co (搜索) (known as MSD outside the U.S. and Canada), demonstrating strong industry validation of the proximity-based therapeutic approach.
Dr. Conti's track record of rapidly translating discovery programs into IND-stage development will be critical as Proxygen (搜索) transitions from a discovery-focused organization to a clinical-stage company. Her experience establishing TPD platforms and advancing multiple programs simultaneously aligns with Proxygen's ambitious pipeline advancement goals.